Generalized verrucosis in a patient with GATA2 deficiency

British Journal of Dermatology

Volumn 170, Issue 5, 2014, Pages 1182-1186

  West, E S ^a   Kingsbery, M Y ^a   Mintz, E M ^a   Hsu, A P ^b   Holland, S M ^b   Rady, P L ^c   Tyring, S K ^c   Grossman, M E ^a  

^a NewYork Presbyterian Hospital   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c University of Texas Health Science Center at Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; ETRETIN; FLUOROURACIL; GAMMA INTERFERON; IMIQUIMOD; TRANSCRIPTION FACTOR GATA 2;

ADULT; ANEMIA; ARTICLE; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DISEASE DURATION; DRUG DOSE REDUCTION; GATA 2 DEFICIENCY; GENERALIZED VERRUCOSIS; GENETIC DISORDER; HUMAN; HUMAN PAPILLOMA VIRUS TYPE 57; IMMUNE DEFICIENCY; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MONOCYTOPENIA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PAPILLOMATOSIS; PAPULE; PRIORITY JOURNAL; SAUDI ARABIA; SKIN BIOPSY; THROMBOCYTOPENIA; TREATMENT DURATION; WART VIRUS; YOUNG ADULT; DEFICIENCY; GENETICS; MUTATION; PEDIGREE; SKIN TUMOR; VERRUCA VULGARIS;

GATA2 TRANSCRIPTION FACTOR; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; MUTATION; PEDIGREE; SKIN NEOPLASMS; WARTS; YOUNG ADULT;

EID: 84900992796     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12794     Document Type: Article

References (28)

1. Sri JC, Dubina MI, Kao GF, et al,. Generalized verrucosis: a review of the associated diseases, evaluation, and treatments. J Am Acad Dermatol 2012; 66: 292-311.
2. Vu J, Wallace GR, Singh R, et al,. Common variable immunodeficiency syndrome associated with epidermodysplasia verruciformis. Am J Clin Dermatol 2007; 8: 307-10.
3. Chu EY, Freeman AF, Jing H, et al,. Cutaneous manifestations of DOCK8 deficiency syndrome. Arch Dermatol 2012; 148: 79-84.
4. Leiding JW, Holland SM,. Warts and all: human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol 2012; 130: 1030-48.
5. Vinh DC, Patel SY, Uzel G, et al,. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010; 115: 1519-29.
6. Hsu AP, Sampaio EP, Khan J, et al,. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011; 118: 2653-5.
7. Spinner MA, Sanchez LA, Hsu AP, et al,. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood 2014; 123: 809-21.
8. Berkhout RJ, Tieben LM, Smits HL, et al,. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 1995; 33: 690-5.
9. Bigley V, Haniffa M, Doulatov S, et al,. The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. J Exp Med 2011; 208: 227-34.
10. Ostergaard P, Simpson MA, Connell FC, et al,. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011; 43: 929-31.
11. Hahn CN, Chong CE, Carmichael CL, et al,. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 2011; 43: 1012-17.
12. Ling K, Ottersbach K, van Hamburg JP, et al,. GATA-2 plays two functionally distinct roles during the ontogeny of hematopoietic stem cells. J Exp Med 2004; 200: 871-82.
13. Kazenwadel J, Secker GA, Liu YJ, et al,. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood 2012; 119: 1283-91.
14. Ostrow RS, Manias D, Mitchell AJ, et al,. Epidermodysplasia verruciformis: a case associated with primary lymphatic dysplasia, depressed cell-mediated immunity, and Bowen's disease containing human papillomavirus 16 DNA. Arch Dermatol 1987; 123: 1511-16.
15. Kreuter A, Hochdorfer B, Brockmeyer NH, et al,. A human papillomavirus-associated disease with disseminated warts, depressed cell-mediated immunity, primary lymphedema, and anogenital dysplasia: WILD syndrome. Arch Dermatol 2008; 144: 366-72.
16. Rodrigues NP, Boyd AS, Fugazza C, et al,. GATA-2 regulates granulocyte-macrophage progenitor cell function. Blood 2008; 112: 4862-73.
17. Carneiro-Sampaio M, Coutinho A,. Immunity to microbes: lessons from primary immunodeficiencies. Infect Immun 2007; 75: 1545-55.
18. Hartmann P, Plum G,. Immunological defense mechanisms in tuberculosis and MAC-infection. Diagn Microbiol Infect Dis 1999; 34: 147-52.
19. Mace EM, Hsu AP, Monaco-Shawver L, et al,. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56(bright) subset. Blood 2013; 121: 2669-77.
20. Malejczyk J, Majewski S, Jablonska S,. Cellular immunity in cutaneous and genital HPV infections. Clin Dermatol 1997; 15: 261-74.
21. Bonagura VR, Hatam LJ, Rosenthal DW, et al,. Recurrent respiratory papillomatosis: a complex defect in immune responsiveness to human papillomavirus-6 and -11. APMIS 2010; 118: 455-70.
22. Chan S, Chew S, Egawa K, et al,. Phylogenetic analysis of the human papillomavirus type 2 (HPV-2), HPV-27, HPV-57 group, which is associated with common warts. Virology 1997; 239: 296-302.
23. Faluhelyi Z, Rodler I, Csejtey A, et al,. All-trans retinoic acid (ATRA) suppresses transcription of human papillomavirus type 16 (HPV16) in a dose-dependent manner. Anticancer Res 2004; 24: 807-9.
24. Rivera A, Tyring SK,. Therapy of cutaneous human Papillomavirus infections. Dermatol Ther 2004; 17: 441-8.
25. Kono T, Kondo S, Pastore S, et al,. Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res 1994; 13: 71-6.
26. Harwood CA, Perrett CM, Brown VL, et al,. Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. Br J Dermatol 2005; 152: 122-9.
27. Venugopal SS, Murrell DF,. Recalcitrant cutaneous warts treated with recombinant quadrivalent human papillomavirus vaccine (types 6, 11, 16, and 18) in a developmentally delayed, 31-year-old white man. Arch Dermatol 2010; 146: 475-7.
28. Cuellar-Rodriguez J, Gea-Banacloche J, Freeman AF, et al,. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood 2011; 118: 3715-20.